SCHEMBL4865031

SCHEMBL4865031

CCCCCC(CC)OC(=O)CO

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
MAPK1 P28482 1/20 0.50
PRKCA P17252 2/20 0.46
PRKCD Q05655 2/20 0.46
PRKCE Q02156 1/20 0.44
PRKCQ Q04759 1/20 0.44
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
FAAH O00519 5/20 0.41
CNR1 P21554 2/20 0.41
CNR2 P34972 2/20 0.41
HPGD P15428 1/20 0.41
EPHX2 P34913 1/20 0.40
CTSK P43235 1/20 0.39
GPR84 Q9NQS5 3/20 0.38
FFAR1 O14842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2285801 0.86 MAPT (0.56) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL7117627 0.86 MAPT (0.47) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL1401309 0.85 MAPT (0.56) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL3392995 0.85 MAPK1 (0.65) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL3712813 0.85 MAPT (0.50) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL4816642 0.85 MAPT (0.50) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL13415721 0.85 MAPT (0.50) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL1071033 0.85 MAPK1 (0.65) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL6906747 0.85 MAPT (0.50) MAPTMAPK1PRKCAPRKCDPRKCE
SCHEMBL6904773 0.85 MAPT (0.50) MAPTMAPK1PRKCAPRKCDPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459581-B2 Anti-bacterial compounds GIVAUDAN S.A. (CH) 2008-12-02 US claimed
US-20080070985-A1 Anti-Bacterial Compounds BEIERSDORF AG (DE) 2008-03-20 US claimed
EP-1786756-A1 ANTI-BACTERIAL COMPOUNDS Givaudan SA (CH) 2007-05-23 EP claimed
WO-2006026876-A1 ANTI-BACTERIAL COMPOUNDS GIVAUDAN SA (CH) 2006-03-16 WO claimed
US-20140287361-A1 RESIST COMPOSITION AND RESIST PATTERN FORMING METHOD TOKYO OHKA KOGYO CO., LTD. (JP) 2014-09-25 US disclosed
US-20140287361-A1 RESIST COMPOSITION AND RESIST PATTERN FORMING METHOD TOKYO OHKA KOGYO CO., LTD. (JP) 2014-09-25 US disclosed
US-7459581-B2 Anti-bacterial compounds GIVAUDAN S.A. (CH) 2008-12-02 US disclosed
US-20080070985-A1 Anti-Bacterial Compounds BEIERSDORF AG (DE) 2008-03-20 US disclosed
EP-1786756-A1 ANTI-BACTERIAL COMPOUNDS Givaudan SA (CH) 2007-05-23 EP disclosed
WO-2006026876-A1 ANTI-BACTERIAL COMPOUNDS GIVAUDAN SA (CH) 2006-03-16 WO disclosed
US-5015419-A Bactericides or fungicides and yarn lubricants for textiles THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1991-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070985-A1 Anti-Bacterial Compounds H1-0, H1-3, LBR MAPT 4634/4885MAPK1 1717/4885PRKCA 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.